

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 May 2011 (26.05.2011)

(10) International Publication Number
WO 2011/062637 A1

(51) International Patent Classification:
C07K 14/00 (2006.01) *A61K 39/002* (2006.01)

(21) International Application Number:
PCT/US2010/003017

(22) International Filing Date:
18 November 2010 (18.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/281,679 18 November 2009 (18.11.2009) US

(71) Applicants (for all designated States except US):
HAWAII BIOTECH, INC. [US/US]; 99-193 Aiea Heights Dr., Ste 200, Aiea, HI 96701 (US). **UNIVERSITY OF HAWAII** [US/US]; Office of Technology Transfer and Economic Development, 2800 Woodlawn Drive, Suite 280, Honolulu, HI 96822 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLEMENTS, David, E.** [US/US]; 1322 10th Ave, Honolulu, HI 96816 (US). **PUSIC, Kae, Miriam** [US/US]; 1888 Kalakaua Ave., Apt #1301, Honolulu, HI 96815 (US). **HUI, George, S., N.** [US/US]; 7796 Waikapu Lp, Honolulu, HI 96825 (US).

(74) Common Representative: **HAWAII BIOTECH, INC.**; Attn: Kent E. Harada, 99-193 Aiea Heights Dr., Ste 200, Aiea, HI 96701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ENHANCED MALARIA MSP-1 SUBUNIT VACCINE

(57) Abstract: Recombinant subunit proteins derived from the MSP-1 C-terminal region of the parasite *Plasmodium falciparum* are described that have enhanced immunogenic properties. Selected regions of p33 have been combined with pi 9 to enhance the immunogenic potential of the p19 core region. As the constructs represent discontinuous segments fused to create unique proteins, the recombinant proteins expressed are not found in nature. The enhanced immunogenic potential of the disclosed recombinant proteins provided for strong, consistent and specific antibody responses. The disclosed recombinant subunit proteins are vaccine candidates for protection against infection with malaria.



WO 2011/062637 A1